These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19771322)

  • 1. Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization.
    Boada M; Ortiz P; Anaya F; Hernández I; Muñoz J; Núñez L; Olazarán J; Roca I; Cuberas G; Tárraga L; Buendia M; Pla RP; Ferrer I; Páez A
    Drug News Perspect; 2009; 22(6):325-39. PubMed ID: 19771322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Human Albumin Grifols 5% in plasmapheresis: a new therapy involving beta-amyloid mobilisation in Alzheimer's disease].
    Boada-Rovira M
    Rev Neurol; 2010 Mar; 50 Suppl 5():S9-18. PubMed ID: 20517868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.
    Boada M; Anaya F; Ortiz P; Olazarán J; Shua-Haim JR; Obisesan TO; Hernández I; Muñoz J; Buendia M; Alegret M; Lafuente A; Tárraga L; Núñez L; Torres M; Grifols JR; Ferrer I; Lopez OL; Páez A
    J Alzheimers Dis; 2017; 56(1):129-143. PubMed ID: 27911295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study.
    Boada M; Ramos-Fernández E; Guivernau B; Muñoz FJ; Costa M; Ortiz AM; Jorquera JI; Núñez L; Torres M; Páez A
    Neurologia; 2016 Sep; 31(7):473-81. PubMed ID: 25023458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin.
    Cuberas-Borrós G; Roca I; Boada M; Tárraga L; Hernández I; Buendia M; Rubio L; Torres G; Bittini Á; Guzmán-de-Villoria JA; Pujadas F; Torres M; Núñez L; Castell J; Páez A
    J Alzheimers Dis; 2018; 61(1):321-332. PubMed ID: 29154283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
    Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS
    Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.
    Boada M; López OL; Olazarán J; Núñez L; Pfeffer M; Paricio M; Lorites J; Piñol-Ripoll G; Gámez JE; Anaya F; Kiprov D; Lima J; Grifols C; Torres M; Costa M; Bozzo J; Szczepiorkowski ZM; Hendrix S; Páez A
    Alzheimers Dement; 2020 Oct; 16(10):1412-1425. PubMed ID: 32715623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma amyloid beta42 and amyloid beta40 levels are associated with early cognitive dysfunction after cardiac surgery.
    Evered LA; Silbert BS; Scott DA; Maruff P; Laughton KM; Volitakis I; Cowie T; Cherny RA; Masters CL; Li QX
    Ann Thorac Surg; 2009 Nov; 88(5):1426-32. PubMed ID: 19853085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease.
    Maczurek A; Hager K; Kenklies M; Sharman M; Martins R; Engel J; Carlson DA; Münch G
    Adv Drug Deliv Rev; 2008; 60(13-14):1463-70. PubMed ID: 18655815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.
    Relkin NR; Szabo P; Adamiak B; Burgut T; Monthe C; Lent RW; Younkin S; Younkin L; Schiff R; Weksler ME
    Neurobiol Aging; 2009 Nov; 30(11):1728-36. PubMed ID: 18294736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study.
    Freund-Levi Y; Hjorth E; Lindberg C; Cederholm T; Faxen-Irving G; Vedin I; Palmblad J; Wahlund LO; Schultzberg M; Basun H; Eriksdotter Jönhagen M
    Dement Geriatr Cogn Disord; 2009; 27(5):481-90. PubMed ID: 19439966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.
    Papaliagkas VT; Anogianakis G; Tsolaki MN; Koliakos G; Kimiskidis VK
    Dement Geriatr Cogn Disord; 2009; 28(1):30-5. PubMed ID: 19628938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging insights into the role of albumin with plasma exchange in Alzheimer's disease management.
    Costa M; Páez A
    Transfus Apher Sci; 2021 Jun; 60(3):103164. PubMed ID: 34083161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The capacity of albumin to bind to beta-amyloid].
    Costa M; Ortiz AM; Jorquera JI
    Rev Neurol; 2010 Mar; 50 Suppl 5():S1-4. PubMed ID: 20517864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic plasmapheresis and experience in Alzheimer's disease].
    Anaya F
    Rev Neurol; 2010 Mar; 50 Suppl 5():S5-8. PubMed ID: 20517867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.
    Pride M; Seubert P; Grundman M; Hagen M; Eldridge J; Black RS
    Neurodegener Dis; 2008; 5(3-4):194-6. PubMed ID: 18322388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress.
    Boada M; López O; Núñez L; Szczepiorkowski ZM; Torres M; Grifols C; Páez A
    Alzheimers Dement (N Y); 2019; 5():61-69. PubMed ID: 30859122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic albumin binding to remove amyloid-β.
    Costa M; Ortiz AM; Jorquera JI
    J Alzheimers Dis; 2012; 29(1):159-70. PubMed ID: 22232005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.
    Imbimbo BP; Peretto I
    Curr Opin Investig Drugs; 2009 Jul; 10(7):721-30. PubMed ID: 19579178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.